CDC reports sharp rise in U.S. rabies exposures and anti-rabies immunoglobulin use. Kamada confirms sufficient KedRAB supply to meet higher demand. Rising rabies exposures increase demand for Kamada's KedRAB, supporting higher sales and revenue.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | 2 |
| total | individual payouts | |
|---|---|---|
| 2026 | 0.42 |
—
—
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 55.64 | 78.44 | 75.47 | 70.13 |
| Receivables | 25.84 | 27.09 | 32.66 | 42.57 |
| Inventory | 88.48 | 78.82 | 84.94 | 86.88 |
| Other | — | — | — | — |
| 169.96 | 184.35 | 193.08 | 199.57 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 33.07 | 37.41 | 35.35 | 40.68 |
| ST’ Debt | 15.00 | 10.18 | 9.92 | 6.03 |
| Other | — | — | — | — |
| 49.59 | 49.39 | 47.39 | 49.16 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 45.24 | 54.92 | — | — |
—
|
| ’25 | 44.02 | 44.75 | 47.01 | 44.68 |
180.46
|
| ’24 | 37.74 | 42.47 | 41.74 | 39.01 |
160.95
|
| ’23 | 30.71 | 37.44 | 37.93 | 36.43 |
142.52
|
| ’22 | 28.09 | 23.59 | 32.22 | 45.44 |
129.34
|
| ’21 | 24.90 | 24.24 | 23.03 | 31.47 |
103.64
|
| ’20 | 33.29 | 33.09 | 35.33 | 31.54 |
133.25
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.29) | 18.07 | — | — |
—
|
| ’25 | (0.51) | 8.02 | 10.42 | 7.57 |
25.49
|
| ’24 | 1.02 | 13.96 | 22.21 | 10.40 |
47.59
|
| ’23 | (2.85) | 1.84 | 0.92 | 4.41 |
4.32
|
| ’22 | 5.47 | 10.89 | 5.49 | 6.74 |
28.59
|
| ’21 | 2.10 | (3.28) | (2.67) | (4.97) |
(8.82)
|
| ’20 | (1.92) | 10.66 | (2.38) | 12.75 |
19.11
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.26) | 15.96 | — | — |
—
|
| ’25 | (1.97) | 6.01 | 6.83 | 4.79 |
15.65
|
| ’24 | (1.66) | 10.95 | 20.09 | 7.47 |
36.86
|
| ’23 | (3.94) | 0.79 | (0.81) | 2.44 |
(1.53)
|
| ’22 | 4.95 | 10.21 | 3.88 | 5.77 |
24.80
|
| ’21 | 1.97 | (4.61) | (4.19) | (5.71) |
(12.55)
|
| ’20 | (2.82) | 9.66 | (3.85) | 10.63 |
13.62
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.07 | 0.16 | — | — |
—
|
| ’25 | 0.07 | 0.13 | 0.09 | 0.06 |
0.35
|
| ’24 | 0.04 | 0.08 | 0.07 | 0.07 |
0.25
|
| ’23 | (0.04) | 0.04 | 0.06 | 0.09 |
0.15
|
| ’22 | (0.04) | (0.09) | 0.01 | 0.07 |
(0.05)
|
| ’21 | 0.06 | 0.02 | (0.02) | (0.11) |
(0.05)
|
| ’20 | 0.12 | 0.08 | 0.15 | 0.04 |
0.38
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | 3.72 | 4.02 | 4.74 | 5.54 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 6.88 | 6.35 | 6.53 | 9.15 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 380 | 378 | 420 | 462 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.34 | 0.38 | 0.38 | 0.39 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 129.34 | 142.52 | 160.95 | 180.46 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 36.11% | 38.94% | 43.47% | 42.34% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.26) | 8.43 | 13.33 | 23.47 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.75%) | 5.91% | 8.28% | 13.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.32) | 8.28 | 14.46 | 20.20 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.16 | 12.71 | 13.81 | 14.92 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.89 | 2.92 | 2.80 | 3.13 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | (0.05) | 0.17 | 0.25 | 0.35 | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.64 | 0.09 | 0.83 | 0.44 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.08) | (0.12) | (0.19) | (0.17) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.55 | (0.03) | 0.64 | 0.27 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.93 | 5.00 | 4.51 | 4.67 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 44.82 | 48.83 | 57.49 | 57.65 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 38.50 | 23.42 | 20.17 | — | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.44 | 2.11 | 2.18 | 2.26 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.06 | 1.23 | 1.35 | 1.51 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 1.54 | 1.86 | 1.78 | 1.92 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.02 | (173.34) | 7.78 | 22.12 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.59 | 4.32 | 47.59 | 25.49 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.78) | (5.84) | (10.74) | (9.84) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.80 | (1.53) | 36.86 | 15.65 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 63.30 | 120.37 | 134.96 | 145.68 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 47.12 | 15.00 | 10.18 | 9.92 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.86 | (40.64) | (68.25) | (65.55) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 176.02 | 244.02 | 259.46 | 269.07 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.72%) | 2.45% | 3.98% | 5.38% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.50% | 3.09% | 6.55% | 8.06% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.32%) | 3.94% | 5.74% | 7.64% | — | — | — |
ROE
|
Kamada Ltd. (KMDA), an Israeli biopharmaceutical leader in specialty plasma-derived therapeutics, has demonstrated resilient growth amid a decade of volatility, including COVID-19 supply chain shocks. Revenue compounded at 9.1% annually from 2016 to 2023, rising 84% to $142.5 million, fueled by milestones like the 2021 FDA approval for CYTOGAM and 2023 EUA for immunoglobulin treatments. Operational efficiency shines through an 86% surge in revenue per employee to $383,221 with stable headcount, and gross margins expanded 58% to 43.5%, signaling strong pricing power and cost controls in a competitive biotech landscape.
Profitability has turned a corner, with 2023 net income flipping to $14.5 million ($0.25 EPS) from prior losses, alongside ROE at 5.7% and ROIC at 6.6%. Free cash flow exploded to $36.9 million, enabling a 78% debt reduction to a $68 million net cash position. Valuation metrics are compelling—trailing P/E at 23.4, P/S at 2.2, and EV/FCF at 7.8—with shares trading at a 30-75% discount to analyst targets, implying significant re-rating potential.
Analysts forecast 32% revenue growth to $189 million in 2024 and a 10% forward CAGR through 2026, with net income scaling to $35.5 million by then. While risks like plasma supply geopolitics and competition loom, KMDA’s efficiency rebound, FCF surge, and pipeline progress position it for asymmetric upside in biotech recovery.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.